Puente-Moncada N

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity.

Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, ..., Woods NB, Järås M

Blood Adv - (-) - [2023-07-28; online 2023-07-28]

Swedish Metabolomics Centre (SMC) [Service]

The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.

von Palffy S, Thorsson H, Peña-Martínez P, ..., Lilljebjörn H, Fioretos T

Blood Adv - (-) - [2022-11-16; online 2022-11-16]

Clinical Genomics Lund [Service]